Oculis Holding AG Ordinary shares (OCS) Stock Price

OCSStock
$12.2125.32%52W
Market Cap$678.00M
P/E
PEG Ratio
Div yield
Beta0.24

OCS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-70.72%
Price vs S&P 500 (4W)1.15%
VGM Score19.30

OCS Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.47-$0.20+58.17%(+$0.27)
Q1 2026-$0.51-$0.61-19.79%(-$0.10)
Q4 2025-$0.51-$0.52-2.15%(-$0.01)
Q3 2025-$0.51-$0.40+22.25%(+$0.11)
Q2 2025-$0.55-$0.61-9.26%(-$0.05)

OCS Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.33
4.38
4.38
4.40

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
OCSOculis Holding AG Ordinary shares
F$12.21
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Oculis Holding AG Ordinary shares

Oculis Holding AG is a biopharmaceutical company developing topical treatments and disease-modifying therapies for ophthalmological conditions. Its pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and related neuro-ophthalmological disorders. The company's candidates target prevalent eye conditions including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.